John Sourbeer

Stock Analyst at UBS

(0)
# 4347
Out of 5,243 analysts
46
Total ratings
41.67%
Success rate
-10.71%
Average return
19 Stocks
Name Action Price Target Current % Upside Ratings Updated
West Pharmaceutical ...
Upgrades: Buy
350 390
327.93 18.93% 3 Dec 12, 2024
Pacific Biosciences
Downgrades: Neutral
2
1.75 14.29% 3 Nov 11, 2024
Illumina
Maintains: Neutral
133 145
135.94 6.66% 3 Nov 5, 2024
QuidelOrtho
Upgrades: Neutral
42 50
41.49 20.51% 2 Sep 19, 2024
Singular Genomics Sy...
Maintains: Neutral
12 15
19.68 -23.78% 2 Mar 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
15 17
7.49 126.97% 4 Mar 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
452 480
336.9 42.48% 4 Mar 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
7 8
2.74 173.72% 2 Mar 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
94 102
59.33 71.92% 3 Mar 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
58 64
n/a n/a 6 Feb 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
50 44
45.51 -4.94% 3 Nov 2, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
7 3
n/a n/a 2 Oct 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
50
15.39 224.89% 1 Feb 2, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
68
n/a n/a 1 Sep 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
270
198.51 36.01% 1 Sep 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
142 128
111.39 14.91% 2 Jul 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
13 4
n/a n/a 2 Mar 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
22
22.15 -0.68% 1 Aug 10, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
23
n/a n/a 1 Feb 22, 2021